Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD) — Matthew R. Smith (2019) | RDL Network
Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)
Matthew R. Smith, Shahneen Sandhu, William Kevin Kelly, Howard I. Scher, Eleni Efstathiou, Primo N. Lara, Evan Y. Yu, Daniel J. George, Kim N., Jason M. Summa, Nishi Kothari, Xin Zhao, Byron M. Espina, Deborah Ricci, Jason S. Simon, NamPhuong Tran, Karim Fizazi
Matthew R. Smith, Karim Fizazi, Shahneen Sandhu, William Kevin Kelly, Eleni Efstathiou, Primo N. Lara, Evan Y. Yu, Daniel J. George, Kim N., Fred Saad, Jason M. Summa, Jamie Freedman, Gary Mason, Byron M. Espina, Eugene Zhu, Deborah Ricci, Linda A. Snyder, Jason S. Simon, Shinta Cheng, Howard I. Scher
Matthew R. Smith, Shahneen Sandhu, Daniel J. George, K.N. Chi, Fred Saad, Antoine Thiery-Vuillemin, O. Ståhl, David Olmos, Daniel C. Danila, Rustem Gafanov, Elena Castro, Helen Moon, Anthony M. Joshua, Gary Mason, Byron M. Espina, Y. Liu, Katherine B. Bevans, Angela Lopez‐Gitlitz, Peter Francis, Karim Fizazi
Matthew R. Smith, Howard I. Scher, Shahneen Sandhu, Eleni Efstathiou, Primo N. Lara, Evan Y. Yu, Daniel J. George, Kim N., Fred Saad, Olof Ståhl, David Olmos, Daniel C. Danila, Gary Mason, Byron M. Espina, Xin Zhao, Karen A. Urtishak, Peter Francis, Angela Lopez‐Gitlitz, Karim Fizazi, Francis Parnis, Anthony M. Joshua, Lisa G. Horvath,
Matthew R. Smith, Shahneen Sandhu, Daniel J. George, Kim Nguyen, Fred Saad, Antoine Thiery-Vuillemin, O. Ståhl, David Olmos, Daniel C. Danila, Rustem Gafanov, Elena Castro, Helen Moon, Anthony M. Joshua, Gary Mason, Byron M. Espina, Yan Liu, Angela Lopez‐Gitlitz, Peter Francis, Katherine B. Bevans, Karim Fizazi
Discussion(0)
No comments yet. Be the first to comment.